PMID- 24550281 OWN - NLM STAT- MEDLINE DCOM- 20140415 LR - 20220408 IS - 1091-6490 (Electronic) IS - 0027-8424 (Print) IS - 0027-8424 (Linking) VI - 111 IP - 7 DP - 2014 Feb 18 TI - Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. PG - 2548-53 LID - 10.1073/pnas.1324297111 [doi] AB - Cancer is widely characterized by the sequential acquisition of genetic lesions in a single lineage of cells. Our previous studies have shown that, in acute myeloid leukemia (AML), mutation acquisition occurs in functionally normal hematopoietic stem cells (HSCs). These preleukemic HSCs harbor some, but not all, of the mutations found in the leukemic cells. We report here the identification of patterns of mutation acquisition in human AML. Our findings support a model in which mutations in "landscaping" genes, involved in global chromatin changes such as DNA methylation, histone modification, and chromatin looping, occur early in the evolution of AML, whereas mutations in "proliferative" genes occur late. Additionally, we analyze the persistence of preleukemic mutations in patients in remission and find CD34+ progenitor cells and various mature cells that harbor preleukemic mutations. These findings indicate that preleukemic HSCs can survive induction chemotherapy, identifying these cells as a reservoir for the reevolution of relapsed disease. Finally, through the study of several cases of relapsed AML, we demonstrate various evolutionary patterns for the generation of relapsed disease and show that some of these patterns are consistent with involvement of preleukemic HSCs. These findings provide key insights into the monitoring of minimal residual disease and the identification of therapeutic targets in human AML. FAU - Corces-Zimmerman, M Ryan AU - Corces-Zimmerman MR AD - Program in Cancer Biology, Ludwig Center, Cancer Institute, Institute for Stem Cell Biology and Regenerative Medicine, and Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305. FAU - Hong, Wan-Jen AU - Hong WJ FAU - Weissman, Irving L AU - Weissman IL FAU - Medeiros, Bruno C AU - Medeiros BC FAU - Majeti, Ravindra AU - Majeti R LA - eng GR - R01 CA188055/CA/NCI NIH HHS/United States GR - U01 HL099999/HL/NHLBI NIH HHS/United States GR - R01 CA086017/CA/NCI NIH HHS/United States GR - T32CA009287-35/CA/NCI NIH HHS/United States GR - T32 CA009287/CA/NCI NIH HHS/United States GR - U01HL099999/HL/NHLBI NIH HHS/United States GR - R01 CA086065/CA/NCI NIH HHS/United States GR - U01 HL099995/HL/NHLBI NIH HHS/United States GR - F31 CA180659/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20140203 PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (Antigens, CD34) SB - IM CIN - Cell Stem Cell. 2014 Apr 3;14(4):421-2. PMID: 24702991 MH - Antigens, CD34/metabolism MH - Base Sequence MH - Clonal Evolution/*genetics MH - Epigenesis, Genetic/*genetics MH - Exome/genetics MH - Flow Cytometry MH - Genotype MH - Hematopoietic Stem Cells/*chemistry MH - Humans MH - Leukemia, Myeloid, Acute/*genetics MH - *Models, Biological MH - Molecular Sequence Data MH - Mutation/genetics MH - Preleukemia/*genetics MH - Sequence Analysis, DNA PMC - PMC3932921 OTO - NOTNLM OT - clonal evolution OT - preleukemia COIS- The authors declare no conflict of interest. EDAT- 2014/02/20 06:00 MHDA- 2014/04/16 06:00 PMCR- 2014/08/18 CRDT- 2014/02/20 06:00 PHST- 2014/02/20 06:00 [entrez] PHST- 2014/02/20 06:00 [pubmed] PHST- 2014/04/16 06:00 [medline] PHST- 2014/08/18 00:00 [pmc-release] AID - 1324297111 [pii] AID - 201324297 [pii] AID - 10.1073/pnas.1324297111 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2548-53. doi: 10.1073/pnas.1324297111. Epub 2014 Feb 3.